Here are some gene therapy delivery methods. This page deals mainly with transfection and delivery, whereas [[gene editing|gene-editing]] pertains to the mechanisms of changing the genetic material, which is what gene therapy endeavors to deliver into cells. See also [[cell therapy]].

[[!toc levels=6]]

# naked DNA

# direct mRNA exposure

[Foliar mRNA spray induces protein synthesis in monocot crop and dicot model plant species](https://www.biorxiv.org/content/10.1101/2025.08.07.668951v1)

# nasal

[New intranasal and injectable gene therapy for healthy life extension](https://www.biorxiv.org/content/10.1101/2021.06.26.449305v1)

# hydrodynamic injection

# viruses and viral gene therapy

* [CAV-2 - why a canine virus is a neurobiologist's best friend](http://easco.org/home/sites/default/files/files_rep/pdf/CAV2why%20a%20canine%20virus.pdf)
* AAV
* lentiviral
* rabies virus, as used in neuroscience work

[Epigenetic landscape and AAV targeting of human neocortical cell classes](https://www.biorxiv.org/content/10.1101/555318v1)

[Generation of viral vectors specific to neuronal subtypes of targeted brain regions by Enhancer-Driven Gene Expression (EDGE)](https://www.biorxiv.org/content/10.1101/606467v1.supplementary-material)

[Systematic multi-trait AAV capsid engineering for efficient gene delivery](https://www.biorxiv.org/content/10.1101/2022.12.22.521680v1)

# electroporation

[An efficient electroporation protocol for the genetic modification of mammalian cells](http://biorxiv.org/content/early/2016/09/04/073387) (2016)

# gene gun

# sonoporation

# gas-filled micro-bubbles

# magnetofection and magnetic nanoparticles

* magnetic calcium phosphate nano-formulations

# carbon nanotubes

# quantum dots

* super paramagnetic iron oxide nanoparticles (SPIONS)

# lipoplexes

# dendrimers

# inorganic nanoparticles

* carbon nanotuubes
* magnetic nanoparticles (see also magnetofection)
* calcium phosphate nanoparticles
* gold nanoparticles
* quantum dots
* C60 fullerenes
* aminofullerenes
* silica nanoparticles

# gold nanoparticles

# cell-penetrating peptides

# polymerosomes

# liposomes

# polyplexes (DNA + plastic)

* polyion complex micelles (PICs)

# cationic polymers

* collagen
* albumin
* beta-casein
* zein

# cationic lipids

* dioleylpropyl trimethylammonium chloride (DOTMA)
* dioleoyl trimethylammonium propane (DOTAP)

# cationic emulsions

# solid lipid nanoparticles

# virosomes

# protofection

# natural competence

# Ligandal's nano-gobstopper method

(patent) [Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations](https://patents.google.com/patent/CA2924535A1)

conjugation of PEI for DNA binding, histone tail peptide for nuclear localization, poly-glutamic acid, glutamic acid for stabilization and charge balancing or whatever, then you stick DNA to it, and silica coat the whole thing, then add even more cell-targeting stuff to the outside.

# other

* poly lactic-co-glycolic acid (PLGA)-based nanoparticles
* hybrid nanoparticles such as liposome-polycation-DNA (LPD) nanoparticles
* lipopolyplexes
* [Minicircle Inc follistatin gene therapy doesn't work](https://docs.google.com/document/d/e/2PACX-1vT7_6kWkIqrvzFZvs88O_NqVzmn-NPINvHOLM-A6r_ieZyvnJsNVk4FSU7EYrePnQg9gT_3kwahJESZ/pub)
* direct delivery of cas9 protein instead of genetically encoded cas9 editors: [Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins](https://www.nature.com/articles/s41467-025-63167-x)
* [Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids](https://www.biorxiv.org/content/10.1101/538421v1) (2019)
* brain intraparenchymal injection for the delivery of AAV gene therapy into brain ([ref](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940433/)), we should also consider direct intraparenchymal injection for cell therapy as well.

# Directed evolution for viral gene therapy

Adult viral gene therapy presently has many problems including low delivery to cells in the body. In some cases, the gene therapy does not need to be delivered to 100% of the cells in the body. In fact, just delivery to the liver, skin, or some other easily accessible niche is sufficient. However, if you for some reason require whole body transfection, then what to do?

To achieve higher transfection of more cells in the human body, you could develop a process of [[directed evolution]] of viral gene therapy viruses in other mammalians. These viruses would be mutated and tested by sequencing different tissues in animal body as well as assessing immune evasion. Through multiple rounds of selection it may be possible to develop a virus that is able to deliver genetic payloads to most of the cells in the body.

For larger genetic payloads, it may be necessary to instead use a form of cell therapy plus horizontal gene transfer for larger genetic payloads.

# cell therapy

[[!inline  pagenames="cell_therapy"  raw="yes"]]

# hplusroadmap logs

See <http://gnusha.org/logs/2017-01-09.log> for some preliminary stuff.

# Physical (non-viral) delivery

* **Electroporation (in vivo / “gene electrotransfer”)** — robust local transfection of muscle, skin, liver and tumors; active clinical exploration in oncology and vaccines; tunable pulse parameters determine efficacy/toxicity. Reviews and recent data: Hensley *et al.* 2024; Hughes & Kandarian 2022; Conniff *et al.* 2024. [MDPI](https://www.mdpi.com/2076-3417/14/23/11298), [Physiological Journals](https://journals.physiology.org/doi/abs/10.1152/japplphysiol.00088.2022), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11304878/)
* **In utero electroporation (IUE)** — staple for CNS development and fetal gene transfer in rodents; efficient neuronal targeting; still preclinical. Classics & updates: Taniguchi *et al.* 2011; Maeda *et al.* 2024. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3530425/), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0012160624002069)
* **In vivo electroporation (general/overviews)** — broad reviews of electroporation, sonoporation, magnetoporation, optoporation and related physical methods. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6058615/)
* **Microinjection (zygote/embryo)** — used in germline or embryo editing; widely used for CRISPR and prime editing. Recent examples: two-cell microinjection boosts prime editing (2024); zygote microinjection with CRISPR post-vitrification (2024). Cellular microinjection can deliver chemicals and genetic material into the cell. [Nature](https://www.nature.com/articles/s41587-023-02106-x), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11232997/)
* **Hydrodynamic injection (tail-vein & limb-vein)** — rapid, large-volume injections give high hepatocyte (and limb muscle) transfection; standard in small animals; clinical translation via lobe-specific/isolated perfusion is being explored. Reviews, protocols, and variants: Suda *et al.* 2023; Wen *et al.* 2024; Hegge *et al.* 2010; STAR Protocols 2025. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10141091/), [STAR Protocols](https://star-protocols.cell.com/protocols/4187)
* **Ultrasound-mediated transfection (sonoporation)** — ultrasound + microbubbles transiently permeabilize membranes and can open the BBB (FUS-BBBO) to deliver genes or AAV to brain; active preclinical & early clinical work. Reviews/mechanism and AAV+FUS studies: Du *et al.* 2022; Wang *et al.* 2024 (AAV to brain); Kofoed *et al.* 2024; Blesa *et al.* 2023. [Frontiers](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.803055/full), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0169409X24001856), [Cell](https://www.cell.com/trends/molecular-medicine/abstract/S1471-4914%2823%2900285-X), [Science](https://www.science.org/doi/10.1126/sciadv.adf4888)

# Viral vectors

* **AAV gene therapy** — capsid engineering, payload limits, immunogenicity & re-dosing challenges; multiple approvals and intense innovation. Strong 2024–2025 reviews: Wang *et al.* 2024 (Signal Transduct Target Ther); Zwi-Dantsis & Rashid 2025; Ling *et al.* 2023 (neuro). [Nature](https://www.nature.com/articles/s41392-024-01780-w), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11861813/), [PubMed](https://pubmed.ncbi.nlm.nih.gov/37658167/)
* (For breadth: Bulcha *et al.* 2021 review of **AAV/Lenti/Adenovirus** platforms.) [Nature](https://www.nature.com/articles/s41392-021-00487-6)

# Non-viral chemical vectors

* **Lipid nanoparticles (LNPs)** — clinically validated (mRNA vaccines); active work on targeting and **endo/lysosomal escape**. Key reviews spanning fundamentals→frontier: Hou *et al.* 2021; Chatterjee *et al.* 2024 (PNAS, endosomal escape bottleneck); Wang *et al.* 2025 (endo/lysosomal-escapable LNP design); Brimacombe *et al.* 2025 (gene-therapy LNP design). [Nature](https://www.nature.com/articles/s41578-021-00358-0), [PNAS](https://www.pnas.org/doi/10.1073/pnas.2307800120), [MDPI](https://www.mdpi.com/1999-4923/17/7/803), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12274843/)
* **Polymers / polyplexes & hybrids** — PAMAM/PEI/PBAE, polymer–lipid hybrids; ongoing advances in targeting & intracellular trafficking. Good overviews 2023–2025. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11435517/), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0168365924008459)
* **Nanoparticle “lysosome angle” (why it matters)** — many vectors are endocytosed and risk degradation in **lysosomes**, so endosomal escape is pivotal; reviews on mechanisms & strategies (2023–2025). [Science Advances](https://spj.science.org/doi/10.34133/research.0148), [ACS Publications](https://pubs.acs.org/doi/10.1021/acs.langmuir.4c05176), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11243486/)

# “Bleeding-edge” & hybrid systems

* **Focused ultrasound to deliver AAV/genes across BBB** — noninvasive, spatially targeted; rapid progress toward clinical translation. Recent method & engineering papers. [Nature](https://www.nature.com/articles/s41467-024-48974-y), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12105982/)
* **Virus-like particles (VLPs) for CRISPR RNPs** — transient, non-integrating protein delivery with viral entry efficiency; now programmable for tropism. Nature Nano 2025; Mol Ther-Nucleic Acids 2025; proof-of-concept cancer models (2023). [Nature](https://www.nature.com/articles/s41565-024-01851-7), [Cell](https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531%2825%2900011-3), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10192467/)
* **Extracellular vesicles / exosomes** — biologically derived carriers for mRNA/siRNA/CRISPR cargo; active engineering for loading, targeting & endosomal escape. Recent reviews & examples (2024–2025). [Nature](https://www.nature.com/articles/s12276-024-01201-6), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225225/)

# Reviews that each cover multiple modalities

* **Molecular Therapy—Nucleic Acids (2025):** “Advanced delivery systems for gene editing” (viral, non-viral, VLPs; preclinical→clinical). [Cell](https://www.cell.com/molecular-therapy-family/nucleic-acids/pdf/S2162-2531%2825%2900011-3.pdf)
* **AIP Appl. Phys. Rev. (2025):** in-vivo delivery systems for CRISPR (AAV, LNP, others). [AIP Publishing](https://pubs.aip.org/aip/apr/article/12/2/021319/3347618/In-vivo-delivery-systems-for-CRISPR-genome-editing)
* **MDPI Int. J. Mol. Sci. (2024):** Viral and non-viral systems to deliver gene-editing therapeutics (broad survey). [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11242246/)
* **J Nanobiotechnology (2023):** comprehensive non-viral vectors (LNPs, dendrimers, polymers, etc.). [BioMed Central](https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-023-02044-5)
* **Advanced Drug Delivery Reviews (topic collection, 2023):** multiple articles on intracellular barriers and escape. [ScienceDirect](https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews/vol/200/suppl/C)

---

## Notes

* **Electroporation / in vivo / in utero:** IUE is excellent for CNS developmental studies and fetal targeting (rodents). [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3530425/), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0012160624002069)
* **Microinjection:** one of the methods for embryo/zygote editing (CRISPR, base/prime editing). It's not the only method of embryo engineering. [Nature](https://www.nature.com/articles/s41587-023-02106-x), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11232997/)
* **Hydrodynamic injection:** liver-dominant transfection; clinical strategies focus on lobe-specific or isolated-organ approaches to reduce cardiovascular load. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10141091/)
* **Ultrasound transfection:** sonoporation in peripheral tissues and **FUS-BBBO** in brain; multiple comparisons and mechanism papers. [Frontiers](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.803055/full), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0169409X24001856)
* **AAV gene therapy:** best-documented clinical track record; capsid engineering, tropism, immunogenicity & manufacturing are the hot spots. [Nature](https://www.nature.com/articles/s41392-024-01780-w)
* **Lysosomes:** for nanoparticle/LNP delivery, endo/lysosomal trafficking is a bottleneck; modern designs explicitly seek endosomal escape or lysosome-avoidance. [PNAS](https://www.pnas.org/doi/10.1073/pnas.2307800120), [MDPI](https://www.mdpi.com/1999-4923/17/7/803)
* **Lipid nanoparticles:** clinically proven for RNA; expanding to DNA and gene editors with active control over trafficking & release. [Nature](https://www.nature.com/articles/s41578-021-00358-0)

---

## Bibliography

* **Physical methods overview:** Du *et al.* 2018; Mellott *et al.* 2012. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6058615/)
* **Electroporation in vivo:** Hensley *et al.* 2024; Conniff *et al.* 2024. [MDPI](https://www.mdpi.com/2076-3417/14/23/11298), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11304878/)
* **IUE basics & update:** Taniguchi *et al.* 2011; Maeda *et al.* 2024. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3530425/), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0012160624002069)
* **Hydrodynamic delivery:** Suda *et al.* 2023; Wen *et al.* 2024. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10141091/)
* **Ultrasound/sonoporation:** Du *et al.* 2022; Ye *et al.* 2024 (AAV+FUS to brain). [Frontiers](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2021.803055/full), [ScienceDirect](https://www.sciencedirect.com/science/article/pii/S0169409X24001856)
* **AAV reviews:** Wang *et al.* 2024; Zwi-Dantsis & Rashid 2025. [Nature](https://www.nature.com/articles/s41392-024-01780-w), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11861813/)
* **LNPs & endosomal escape:** Hou *et al.* 2021; Chatterjee *et al.* 2024; Wang *et al.* 2025. [Nature](https://www.nature.com/articles/s41578-021-00358-0), [PNAS](https://www.pnas.org/doi/10.1073/pnas.2307800120), [MDPI](https://www.mdpi.com/1999-4923/17/7/803)
* **Broad “all-methods” reviews:** Cavazza *et al.* 2025; Taghdiri *et al.* 2024; Wang *et al.* 2023 (non-viral vectors). [Cell](https://www.cell.com/molecular-therapy-family/nucleic-acids/pdf/S2162-2531%2825%2900011-3.pdf), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11242246/), [BioMed Central](https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-023-02044-5)
* **VLPs for CRISPR:** Ling *et al.* 2025; Hu *et al.* 2023. [Nature](https://www.nature.com/articles/s41565-024-01851-7), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10192467/)
* **EVs/exosomes for nucleic acids:** Kim *et al.* 2024; Iqbal *et al.* 2024. [Nature](https://www.nature.com/articles/s12276-024-01201-6), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11225225/)



